Invitae Valuation
Is NVTA.Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NVTA.Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NVTA.Q's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NVTA.Q's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NVTA.Q?
Key metric: As NVTA.Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NVTA.Q's PS Ratio? | |
|---|---|
| PS Ratio | 0.0002x |
| Sales | US$481.58m |
| Market Cap | US$114.60k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | -3.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NVTA.Q's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
FCHS First Choice Healthcare Solutions | 1.6x | n/a | US$118.6k |
ETAO.F ETAO International | 0.00003x | n/a | US$1.5k |
MEDV.F Medivolve | 0.3x | n/a | US$177.0k |
CBDS Cannabis Sativa | 0.9x | n/a | US$748.2k |
NVTA.Q Invitae | 0.0002x | n/a | US$114.6k |
Price-To-Sales vs Peers: NVTA.Q is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does NVTA.Q's PS Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: NVTA.Q is good value based on its Price-To-Sales Ratio (0x) compared to the US Healthcare industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is NVTA.Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.0002x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NVTA.Q's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Elevance Health
US$95.8b
Operates as a health benefits company in the United States.
ELV
US$410.89
7D
-4.2%
1Y
-10.0%
CVS Health
US$68.0b
Provides health solutions in the United States.
CVS
US$54.27
7D
-11.9%
1Y
-21.5%
Align Technology
US$16.4b
Designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally.
ALGN
US$215.03
7D
-4.4%
1Y
4.9%